Abstract
This chapter covers the delicate balance of the use of anticoagulation in older surgical patients, including those undergoing cardiothoracic (CT) surgery, and those with existing prosthetic valves who undergo other surgeries. Increasing age, alone, augments the risk of thromboembolic events in addition to comorbidities commonly seen in older patients (prior stroke, diabetes, atrial fibrillation and cancer). Older patients are also more prone to bleeding due to inadvertent over-anticoagulation, comorbidites (GI bleeding), and other medications affecting bleeding. Managing the older surgical patient on chronic oral anticoagulation therapy (OAT), when to stop therapy, when to use bridging therapy with heparin, when and how to reverse OAT, and how to resume OAT is covered. This section includes recommendations for patients with prosthetic heart valves. Strategies for venothromoembolism (VTE) prophylaxis in the perioperative period of specific surgeries is presented with multiple agents. Lastly, post-surgical conditions requiring anticoagulation such as VTE, atrial fibrillation, myocardial infarction, and valve implantation are presented. Age-specific reductions in warfarin loading and maintenance doses as well as strategies to reduce major bleeding events and intracranial hemorrhage are covered.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Douketis JD, Berger PB, Dunn AS, et al. The perioperative management of antithrombotic therapy. American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133:299–339S.
Gurwitz JH, Field TS, Harrold LR. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003;289(9):1107–16.
Classen DC, Jaser L, Budnitz DS. Adverse drug events among hospitalized Medicare patients: epidemiology and national estimates from a new approach to surveillance. Jt Comm J Qual Patient Saf. 2010;36(1):12–21.
Michaels AD, Spinler SA, Leeper B, et al. Medication errors in acute cardiovascular and stroke patients: a scientific statement from the American Heart Association. Circulation. 2010;121(14):1664–82.
Franchini M. Hemostasis and aging. Crit Rev Oncol Hematol. 2006;60(2):144–51.
Wilkerson WR, Sane DC. Aging and thrombosis. Semin Thromb Hemost. 2002;28(6):555–68.
Abatte R, Prisco D, Rostagno C, et al. Age-related changes in the hemostatic system. Int J Clin Lab Res. 1993;23:1–2.
Torn M, Bollen WL, van der Meer FJ, et al. Risks of oral anticoagulant therapy with increasing age. Arch Intern Med. 2005;165(13):1527–32.
Anonymous. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449–57.
Man-Son-Hing M, Laupacis A. Balancing the risks of stroke and upper gastrointestinal tract bleeding in older patients with atrial fibrillation. Arch Intern Med. 2002;162(5):541–50.
Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 1994;120:897–902.
Nutescu EA, Shapiro NL, Ibrahim S, West P. Warfarin and its interactions with foods, herbs and other dietary supplements. Expert Opin Drug Saf. 2006;5(3):433–51.
Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother. 2007;5(4):345–51.
Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:204S–33.
Garcia D, Regan S, Crowther M, et al. Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest. 2005;127:2049–56.
Kearon C, Kahn S, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence based clinical practice guidelines (8th edition). Chest. 2008;133(6 suppl):4545–5455.
Man-Son-Hing M, Laupacis A. Anticoagulant-related bleeding in older persons with atrial fibrillation: physicians’ fears often unfounded. Arch Intern Med. 2003;163:1580–6.
Jacobs LG. Warfarin pharmacology, clinical management, and evaluation of hemorrhagic risk for the elderly. Clin Geriatr Med. 2006;22:17–18i.
Siguret V, Gouin I, Debray M. Initiation of warfarin therapy in elderly medical inpatients: a safe and accurate regimen. Am J Med. 2005;118:137–42.
Beyth RJ, Quinn L, Landefeld CS. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized, controlled trial. Ann Intern Med. 2000;133:687–95.
Tang EO, Lai CS, Lee KK, et al. Relationship between patients’ warfarin knowledge and anticoagulation control. Ann Pharmacother. 2003;37:34–9.
Bruno JJ. Ellis JJ.Herbal use among US elderly: 2002 National Health Interview Survey. Ann Pharmacother. 2005 Apr;39(4):643–8.
Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline update for coronary bypass graft surgery: summary article. J Am Coll Cardiol. 2004;44:1146.
Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation. Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994;343:687–91.
Fang MC, Chang Y, Hylek EM, et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med. 2004;141:745–52.
Hart RG, Benavente O, Pearce LA. Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: a meta-analysis and hypothesis. Cerebrovasc Dis. 1999;9:215–7.
Bungard TJ, Ghali WA, McAlister FA, et al. Physicians’ perceptions of the benefits and risks of warfarin for patients with nonvalvular atrial fibrillation. CMAJ. 2001;165:301–2.
Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med. 1999;159:677–85.
Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol. 2006;48(3):e1–148.
Thachil J, Gatt A, Martlew V. Management of surgical patients receiving anticoagulation and antiplatelet agents. Br J Surg. 2008;95(12):1437–48.
Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864.
Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA. 2003;290:2685.
Go AS. The epidemiology of atrial fibrillation in elderly persons: the tip of the iceberg. Am J Geriatr Cardiol. 2005;1914:56–61.
Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983–8.
van Aart L, Eijkhout HW, Kamphuis JS, et al. Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial. Thromb Res. 2006;118(3):313–20.
Schulman S. Care of patients receiving long-term anticoagulant therapy. N Engl J Med. 2003;349:675.
Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation. 2004;110(9):e82–292.
Cannegieter SC, Rosendaal FR, Wintzen AR, et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. New Engl J Med. 1995;333:11.
Allou N, Piednoir P, Berroeta C, et al. Incidence and risk factors of early thromboembolic events after mechanical heart valve replacement in patients treated with intravenous unfractionated heparin. Heart. 2009;95(20):1694–700.
Salem DN, O’Gara PT, Madias C, Pauker SG. Valvular and structural heart disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest. 2008;133:593S.
Butchart EG, Gohlke-Barwolf C, Antunes MJ, et al. Recommendations for the management of patients after heart valve surgery. Eur Heart J. 2005;26(22):2463–71.
Becker RC, Meade TW, Berger PB, et al. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest. 2008;133:776S.
Raskob GE, Silverstein R, Bratzler D, et al. Surveillance for deep vein thrombosis and pulmonary embolism: recommendations from a national workshop. Am J of Prev Med. 2010;38:502.
Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J R Soc Med. 1989;82:203.
Geerts MH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: ACCP evidence based clinical pracitce guidelines (8th Edition). Chest. 2008;133(6 suppl):3815–4535.
Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol. 2006;1948:e149–246.
Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131:492–501.
McFalls EO, Ward HB, Moritz TE, et al. Predictors and outcomes of a perioperative myocardial infarction following elective vascular surgery in patients with documented coronary artery disease: results of the CARP trial. Eur Heart J. 2008;29(3):394–401.
King 3rd SB, Smith Jr SC, Hirshfeld Jr JW, et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association task force on practice guidelines: 2007 writing group to review new evidence and update the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention, writing on behalf of the 2005 writing committee. Circulation. 2008;117:261.
Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29:2388.
Horlander KT, Mannino DM, Leeper KV. Pulmonary embolism mortality in the United States, 1979-1998: an analysis using multiple-cause mortality data. Arch Intern Med. 2003;163:1711.
Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d’Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med. 1998;338(7):409–15.
PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d’Embolie Pulmonaire par Interruption Cave) randomized study. Circulation. 2005;112(3):416–22.
Baglin TP, Brush J, Streiff M. Guidelines on use of vena cava filters. Br J Haematol. 2006;134:590.
Hirsh J, Bauer KA, Donati MB, et al. Parenteral anticoagulants: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest. 2008;133:141S.
Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest. 2008;133:340S.
Nutescu E, Shapiro N, Chevalier A. New anticoagulant agents: direct thrombin inhibitors. Cardiol Clin. 2008;26(2):169–87.
Bijsterveld N, Moons A, Boekholdt S, et al. Ability of recombinant factor VIIa to reverse the anticoauglant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation. 2002;106:2550–4.
Konstantinides S. Clinical practice. Acute pulmonary embolism. New Engl J Med. 2008;359(26):2804–13.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Elfrey, M.K., Zieman, S.J. (2011). Anticoagulation in the Older Surgical Patient. In: Katlic, M. (eds) Cardiothoracic Surgery in the Elderly. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-0892-6_17
Download citation
DOI: https://doi.org/10.1007/978-1-4419-0892-6_17
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-0891-9
Online ISBN: 978-1-4419-0892-6
eBook Packages: MedicineMedicine (R0)